Recruiting Leukemia Studies in Chapel Hill
Volrustomig Priming Regimens Exploratory Phase II Platform Study
Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with spe...
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies
SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation grou...
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can i...
Study of AZD9829 in CD123+ Hematological Malignancies
This is a modular, multicentre, open-label, Phase I/II, dose-setting study. AZD9829 will be administered intravenously as monotherapy or in combination in participants with CD123 positive hematologica...
The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias
The most common types of acute leukaemia are acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). AML is a heterogenous clonal disorder of haemopoietic progenitor cells and the most ...
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retreatment with venetoclax-obinutuzumab (VenG) in participants previousl...
Tagraxofusp and Azaxitadine With or Without Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
A treatment cycle is 28 days for Cycle 1 and Cycle 2. Tagraxofusp will be administered at 12 mcg/kg IV over 15 minutes (-5 or +15 minutes) daily for 5 consecutive days (or 5 doses over a period not to...
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignanc...
Omalizumab Weight-Based Dosing Efficacy Trial
This research is being conducted to assess the safety and effectiveness of increased dosing of Omalizumab for food allergies....
About Leukemia Clinical Trials in Chapel Hill
Leukemia is a group of blood cancers that develop in the bone marrow and result in abnormal white blood cells. Types include acute myeloid (AML), acute lymphoblastic (ALL), chronic myeloid (CML), and chronic lymphocytic (CLL). Treatment varies by type and may include chemotherapy, targeted therapy, and stem cell transplant.
There are currently 9 leukemia clinical trials recruiting participants in Chapel Hill, NC. These studies are seeking a combined 854 participants. Research is being sponsored by AstraZeneca, Sellas Life Sciences Group, Johnson & Johnson Enterprise Innovation Inc. and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Leukemia Clinical Trials in Chapel Hill — FAQ
Are there leukemia clinical trials in Chapel Hill?
Yes, there are 9 leukemia clinical trials currently recruiting in Chapel Hill, NC. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Chapel Hill?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Chapel Hill research site will contact you about next steps.
Are clinical trials in Chapel Hill free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Chapel Hill studies also compensate for your time and travel.
What leukemia treatments are being tested?
The 9 active trials in Chapel Hill are testing new therapies including novel drugs, biologics, and treatment approaches for leukemia.
Data updated March 2, 2026 from ClinicalTrials.gov